PMID- 17715065 OWN - NLM STAT- MEDLINE DCOM- 20071017 LR - 20240322 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 104 IP - 35 DP - 2007 Aug 28 TI - Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. PG - 14104-9 AB - Stroke is among the three leading causes of death worldwide and the most frequent cause of permanent disability. Brain ischemia induces an inflammatory response involving activated complement fragments. Here we show that i.v. Ig (IVIG) treatment, which scavenges complement fragments, protects brain cells against the deleterious effects of experimental ischemia and reperfusion (I/R) and prevents I/R-induced mortality in mice. Animals administered IVIG either 30 min before ischemia or after 3 h of reperfusion exhibited a 50-60% reduction of brain infarct size and a 2- to 3-fold improvement of the functional outcome. Even a single low dose of IVIG given after stroke was effective. IVIG was protective in the nonreperfusion model of murine stroke as well and did not exert any peripheral effects. Human IgG as well as intrinsic murine C3 levels were significantly higher in the infarcted brain region compared with the noninjured side, and their physical association was demonstrated by immuno-coprecipitation. C5-deficient mice were significantly protected from I/R injury compared with their wild-type littermates. Exposure of cultured neurons to oxygen/glucose deprivation resulted in increased levels of C3 associated with activation of caspase 3, a marker of apoptosis; both signals were attenuated with IVIG treatment. Our data suggest a major role for complement-mediated cell death in ischemic brain injury and the prospect of using IVIG in relatively low doses as an interventional therapy for stroke. FAU - Arumugam, Thiruma V AU - Arumugam TV AD - Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. FAU - Tang, Sung-Chun AU - Tang SC FAU - Lathia, Justin D AU - Lathia JD FAU - Cheng, Aiwu AU - Cheng A FAU - Mughal, Mohamed R AU - Mughal MR FAU - Chigurupati, Srinivasulu AU - Chigurupati S FAU - Magnus, Tim AU - Magnus T FAU - Chan, Sic L AU - Chan SL FAU - Jo, Dong-Gyu AU - Jo DG FAU - Ouyang, Xin AU - Ouyang X FAU - Fairlie, David P AU - Fairlie DP FAU - Granger, Daniel N AU - Granger DN FAU - Vortmeyer, Alexander AU - Vortmeyer A FAU - Basta, Milan AU - Basta M FAU - Mattson, Mark P AU - Mattson MP LA - eng GR - R01 HL026441/HL/NHLBI NIH HHS/United States GR - HL26441/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20070821 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Complement C5) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Immunologic Factors) SB - IM MH - Animals MH - Brain/*drug effects/immunology/pathology MH - Cell Death/*drug effects MH - Cerebral Cortex/drug effects/immunology/pathology MH - Cerebral Infarction/immunology/*prevention & control MH - Complement C5/deficiency MH - Disease Models, Animal MH - Drug Administration Schedule MH - Immunoglobulins, Intravenous/*therapeutic use MH - Immunologic Factors/therapeutic use MH - Mice MH - Mice, Knockout MH - Neurons/drug effects/*pathology PMC - PMC1955802 COIS- The authors declare no conflict of interest. EDAT- 2007/08/24 09:00 MHDA- 2007/10/18 09:00 PMCR- 2008/02/28 CRDT- 2007/08/24 09:00 PHST- 2007/08/24 09:00 [pubmed] PHST- 2007/10/18 09:00 [medline] PHST- 2007/08/24 09:00 [entrez] PHST- 2008/02/28 00:00 [pmc-release] AID - 0700506104 [pii] AID - 7491 [pii] AID - 10.1073/pnas.0700506104 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14104-9. doi: 10.1073/pnas.0700506104. Epub 2007 Aug 21.